AbCellera Plans Late-Stage Development for ABCL635 in 2027 Following Positive Phase II Results
AbCellera Biologics Inc. (ABCL) reported a transformative third quarter, highlighted by positive Phase II clinical results for its NK3R antibody candidate, ABCL635. CEO Carl L. Hansen indicated that the company intends to initiate late-stage development for this asset in 2027. In addition to clinical progress, management provided reassurance regarding the company's financial stability. AbCellera stated it maintains sufficient liquidity to fund operations for at least the next three years, providing a runway as it advances its therapeutic pipeline.
Tickers: $ABCL
Topics: antibody development biotechnology earnings call phase II results
Read the full article at Seeking Alpha
Part of the story AbCellera Plans Late-Stage Development for ABCL635 in 2027 Following Positive Phase II Results (2 articles)